胰高血糖素受体 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
临床研究通常测量体重、腰围、空腹血糖、糖化血红蛋白和血脂，并记录不良事件。药代动力学评估关注浓度-时间曲线，药效动力学评估关注代谢标志物变化。体重下降由能量摄入减少、能量消耗变化和脂肪组织重塑共同造成，具体权重仍不明确。研究之间的终点定义和随访时长差异使横向比较复杂。
瑞他鲁肽同时激活GLP-1受体、GIP受体和胰高血糖素受体，这三者均属于B类G蛋白偶联受体。受体激活后主要经cAMP信号通路传递效应。GLP-1成分与食欲抑制和胃排空延缓相关，GIP成分影响脂肪组织与胰岛素分泌，胰高血糖素成分则促进肝糖输出和能量消耗。各受体贡献的相对比例在人体中尚未完全量化。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
As a peptide, the compound is generally supplied as a lyophilized powder and stored frozen to slow degradation. Recommended conditions usually sit at minus twenty degrees Celsius or colder, shielded from light and moisture. Solutions are less stable than the dry powder and are often prepared fresh before analysis. Repeated freeze-thaw cycles can drive aggregation, so splitting stock material into small aliquots reduces handling stress and preserves sample integrity.
Quality control of research material relies on several complementary checks. Purity testing confirms the absence of truncated or oxidized peptide species, while water content and counterion analysis show how much mass comes from salts rather than the peptide itself. Sequence verification through tandem mass spectrometry ensures the correct amino acid chain. Because unregulated suppliers vary widely, independent verification of identity and purity is often necessary before a sample enters experiments.
Pituitary pars intermedia dysfunction (PPID), or equine Cushing's disease, is an endocrine disease affecting the pituitary gland of horses. It is most commonly seen in older animals, and is classically associated with the formation of a long, wavy coat (hirsutism) and chronic laminitis.
The Ancient Greek language originally had no word for matter in general, as opposed to raw material suitable for some specific purpose or other, so Aristotle adapted the word for "wood" to this purpose. The idea that everything physical is made of the same basic substance holds up well under modern science, although it may be thought of more in terms of energy or matter/energy. The Latin equivalent of the hyle concept – and later its medieval version – also emerged from Aristotle's notion. The Greek term's Latin equivalent was silva, which literally meant woodland or forest. However, Latin thinkers opted for a word that had a technical sense (rather than literal meaning). This emphasized silva as that of which a thing is made, but one that remained a substratum with changed form. The word materia was chosen instead to indicate a meaning not in handicraft but in the role that mother (mater) plays in conception. Aristotle's concept of hyle is the principle that correlates with shape and this can be demonstrated in the way the philosopher described hyle, saying it is that which receives form or definiteness, that which is formed. It can also be the material cause underlying a change in Aristotelian philosophy. Aristotle explained that "By hyle I mean that which in itself is neither a particular thing nor of a certain quantity nor assigned to any other of the categories by which being is determined." This means that hyle is brought into existence not due to its being its agent or its own actuality but only when form attaches to it.
Wiederrecht GJ, Brown GM (1984). "Purification and properties of the enzymes from Drosophila melanogaster that catalyze the conversion of dihydroneopterin triphosphate to the pyrimidodiazepine precursor of the drosopterins". J. Biol. Chem. 259 (22): 14121–7. doi:10.1016/S0021-9258(18)89865-9. PMID 6438092.
Subsequent clinical research has found that monotherapy with higher dosages of NSAAs than those used in CAB is roughly equivalent to castration in extending life in men with prostate cancer. Moreover, NSAA monotherapy is overall better tolerated and associated with greater quality of life than is castration, which is thought to be related to the fact that testosterone levels do not decrease with NSAA monotherapy and hence by extension that levels of biologically active and beneficial metabolites of testosterone such as estrogens and neurosteroids are preserved. For these reasons, NSAA monotherapy has become an important alternative to castration and CAB in the treatment of prostate cancer. Bicalutamide may be used to reduce the effects of the testosterone flare at the initiation of GnRH agonist therapy. The combination of bicalutamide with an estrogen such as ethinylestradiol sulfonate has been used as a form of CAB and as an alternative to the combination of bicalutamide with surgical or medical castration.
== Firebombing incident == In 2001, Rhéal Mathieu, a member of Front de libération du Québec (FLQ), who in 1967 had been sentenced to nine years in prison for terrorist activities including murder, was convicted of firebombing three Second Cup locations in Montreal. The responsibility for the bombings was claimed by the Brigade d'autodéfense du français (BAF) (translated as Self Defence Brigade of French). BAF claimed it had targeted the stores because the company used its incorporated English name, "Second Cup", demanding the inclusion of French in the name. After the media coverage of the fire bombings, many Second Cup locations in Quebec changed their signs to Les cafés Second Cup.
Sources: en.wikipedia.org
At the age of 19 he was assigned to war work in the Operational Research Section (ORS) of RAF Bomber Command, where he developed analytical methods for calculating the ideal density for bomber formations to help the Royal Air Force bomb German targets during the Second World War. After the war, Dyson was readmitted to Trinity College, where he obtained a BA degree in mathematics. From 1946 to 1949 he was a fellow of his college, occupying rooms just below those of the philosopher Ludwig Wittgenstein, who resigned his professorship in 1947. In 1947 Dyson published two papers in number theory. Friends and colleagues described him as shy and self-effacing, with a contrarian streak that his friends found refreshing but intellectual opponents found exasperating. "I have the sense that when consensus is forming like ice hardening on a lake, Dyson will do his best to chip at the ice", Steven Weinberg said of him. His friend the neurologist and author Oliver Sacks said: "A favourite word of Freeman's about doing science and being creative is the word 'subversive'. He feels it's rather important not only to be not orthodox, but to be subversive, and he's done that all his life."
===== MeSH D08.811.520.241 – carbon-oxygen lyases (EC 4.2) ===== MeSH D08.811.520.241.225 – DNA-(apurinic or apyrimidinic site) lyase MeSH D08.811.520.241.300 – hydro-lyases MeSH D08.811.520.241.300.050 – aconitate hydratase MeSH D08.811.520.241.300.050.500 – iron regulatory protein 1 MeSH D08.811.520.241.300.050.750 – iron regulatory protein 2 MeSH D08.811.520.241.300.150 – carbonic anhydrases MeSH D08.811.520.241.300.150.100 – carbonic anhydrase i MeSH D08.811.520.241.300.150.200 – carbonic anhydrase ii MeSH D08.811.520.241.300.150.300 – carbonic anhydrase iii MeSH D08.811.520.241.300.150.400 – carbonic anhydrase iv MeSH D08.811.520.241.300.150.500 – carbonic anhydrase v MeSH D08.811.520.241.300.200 – cystathionine beta-synthase MeSH D08.811.520.241.300.250 – enoyl-coa hydratase MeSH D08.811.520.241.300.300 – fumarate hydratase MeSH D08.811.520.241.300.500 – phosphopyruvate hydratase MeSH D08.811.520.241.300.500.500 – tau-crystallins MeSH D08.811.520.241.300.550 – porphobilinogen synthase MeSH D08.811.520.241.300.600 – prephenate dehydratase MeSH D08.811.520.241.300.650 – propanediol dehydratase MeSH D08.811.520.241.300.850 – tryptophan synthase MeSH D08.811.520.241.300.900 – urocanate hydratase MeSH D08.811.520.241.300.950 – uroporphyrinogen iii synthetase MeSH D08.811.520.241.700 – polysaccharide-lyases MeSH D08.811.520.241.700.350 – chondroitinases and chondroitin lyases MeSH D08.811.520.241.700.350.500 – chondroitin lyases MeSH D08.811.520.241.700.350.500.500 – chondroitin abc lyase MeSH D08.811.520.241.700.512 – heparin lyase MeSH D08.811.520.241.700.675 – hyaluronoglucosaminidase
=== Young Investigator (YI) Post-Doctoral Programme === (RCB-YI award) has been initiated to nurture outstanding recent PhDs with innovative ideas and the drive to pursue novel discoveries under the mentorship of RCB faculty. RCB-YI award has been instituted for both Indian and Foreign nationals on the competitive basis with initial appointment for three years which is extendable on rigorous review for additional two years.
That promise is null and void if Zverev – and the media – isn't willing to be honest." At the beginning of the 2024 Australian Open, a court official announced that Zverev was scheduled to stand trial before the Tiergarten District Court in Berlin. The timing of the announcement, combined with Zverev's semifinal run at the tournament, brought heightened interest in and scrutiny of the allegations from both the press and the public. The trial began on 31 May 2024. On 7 June 2024, the third day of the trial, the judge agreed to a request by the public prosecution office, endorsed by the alleged victim, to provisionally terminate the proceedings subject to the condition that Zverev pay €200,000, of which €150,000 would go to the German State Treasury and €50,000 to charitable organizations. The trial therefore concluded without a finding of guilt. The prosecutor's request to terminate the proceedings followed an out-of-court agreement between Zverev and the alleged victim, the terms of which were not disclosed. According to his counsel, Zverev entered into the agreement "to put a quick end to the proceedings – above all in the interest of their child", emphasizing that the agreement "includes no determination or admission of guilt".
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
意味着单个分子可同时结合三种代谢受体，而不是只作用于一种。其目的是整合食欲、胰岛素和能量消耗通路，但人体中的协同程度仍在研究。